Table 1.
Selected patient and transplant characteristics of melanoma cases and matched controls, Center for International Blood and Marrow Transplant Research program, 1985–2012.
| Characteristic | Melanoma cases (n=140) | Matched controls (n=557) | ||
|---|---|---|---|---|
| n | % | n | % | |
| Age at transplant,* years | ||||
| <40 | 54 | 38.6 | 214 | 38.4 |
| 40-<55 | 48 | 34.3 | 190 | 34.1 |
| ≥55 | 38 | 27.1 | 153 | 27.5 |
| Sex* | ||||
| Male | 79 | 56.4 | 316 | 56.7 |
| Female | 61 | 43.6 | 241 | 43.3 |
| Indication for transplant* | ||||
| ALL | 25 | 17.9 | 100 | 18.0 |
| AML | 25 | 17.9 | 100 | 18.0 |
| MDS | 13 | 9.3 | 52 | 9.3 |
| Other acute leukemia | 1 | 0.7 | 4 | 0.7 |
| CML | 34 | 24.3 | 136 | 24.4 |
| CMML | 2 | 1.4 | 8 | 1.4 |
| MPN | 9 | 6.4 | 36 | 6.5 |
| CLL | 12 | 8.6 | 48 | 8.6 |
| NHL | 17 | 12.1 | 65 | 11.7 |
| HL | 1 | 0.7 | 4 | 0.7 |
| MM | 1 | 0.7 | 4 | 0.7 |
| Region** | ||||
| United States | 118 | 84.3 | 430 | 77.2 |
| Canada | 15 | 10.7 | 88 | 15.8 |
| Europe | 3 | 2.1 | 20 | 3.6 |
| Australia/New Zealand | 4 | 2.9 | 19 | 3.4 |
| Ambient UVR** | ||||
| Tertile 1 | 42 | 30.0 | 197 | 35.4 |
| Tertile 2 | 41 | 29.3 | 185 | 33.2 |
| Tertile 3 | 57 | 40.7 | 175 | 31.4 |
| Karnofsky score prior to preparative regimen | ||||
| ≥90 | 108 | 77.1 | 410 | 73.6 |
| <90 | 29 | 20.7 | 114 | 20.5 |
| Missing | 3 | 2.1 | 33 | 5.9 |
| Transplant year | ||||
| 1985–1998 | 37 | 26.4 | 203 | 36.4 |
| 1999–2005 | 57 | 40.7 | 173 | 31.1 |
| 2006–2012 | 46 | 32.9 | 181 | 32.5 |
| Donor age, median (range), years | 36 (5–70) | 36 (<1–73) | ||
| Time from transplant to melanoma/study inclusion,* median (range), years | 4 (<1–24) | 4(<1–24) | ||
Abbreviations: ALL - acute lymphocytic leukemia; AML - acute myeloid leukemia; CLL - chronic lymphocytic leukemia; CML - chronic myeloid leukemia; CMML - chronic myelomonocytic leukemia; HL - Hodgkin lymphoma; MDS - myeloproliferative disorder; MM - multiple myeloma; MPN - myeloproliferative neoplasm; mW/m2 - milliWatt per square meter; NHL - non-Hodgkin lymphoma; UVR - ultraviolet radiation.
Four controls were matched to each case by age (± 3 years), sex, first primary disease, and survival time without developing melanoma at least as long as the matched case’s interval from transplant to melanoma.
Ambient UVR was based on the region of patient residence, measured as radiation intensity (mW/m2) and divided into tertiles. If zip code was not available, nearest transplant center was used. Tertile 1: <23.0 mW/m2; Tertile 2: 23.0-<31.6 mW/m2; Tertile 3: ≥31.6mW/m2.